| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Medicine and Bioregulatory Sciences (T.Ma.), University of Tokushima Graduate School of Health Biosciences, Tokushima 770-8503, Japan; Osaka City University (T.Mi.), Osaka 545-0051, Japan; Tottori University (H.H.), Tottori 683-0826, Japan; Kobe University (T.S.), Kobe 650-0017, Japan; Sanyo Osteoporosis Research Foundation (S.O.) Oita 870-0924, Japan; Tsuji Academy of Nutrition (T.H.), Osaka 530-0021, Japan; Keio University Hospital (Y.T.), Tokyo 160-8582, Japan; Tokyo Metropolitan Geriatric Hospital (Y.H.), Tokyo 173-0015, Japan; Kawasaki Medical School (M.F.), Kurashiki 701-0192, Japan; Research Institute and Practice for Involutional Diseases (M.S.), Nagano 399-8101, Japan; and University of Occupational and Environmental Health (T.N.), Fukuoka 807-8582, Japan
Address all correspondence and requests for reprints to: Toshio Matsumoto, M.D., Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Health Biosciences, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. E-mail: toshimat{at}clin.med.tokushima-u.ac.jp.
Context: ED-71 has been shown to increase lumbar bone mineral density (BMD) in osteoporotic subjects. However, vitamin D insufficiency might have influenced the effect of ED-71 on BMD.
Objective: Our objective was to examine whether ED-71 can increase BMD in osteoporotic patients under vitamin D supplementation.
Design, Setting, and Patients: We conducted a randomized, double-blind, placebo-controlled clinical trial of 219 osteoporotic patients (4987 yr of age).
Interventions: Subjects were randomly assigned to receive placebo or 0.5, 0.75, or 1.0 µg/d ED-71 for 12 months. All the subjects received 200 or 400 IU/d vitamin D3.
Main outcome measures: We assessed changes in lumbar and hip BMD and bone turnover markers from baseline.
Results: Lumbar BMD increased with ED-71 treatment for 12 months (2.2, 2.6, and 3.1% from baseline and 2.9, 3.4, and 3.8% vs. placebo group in subjects receiving 0.5, 0.75, and 1.0 µg ED-71, respectively). Total hip BMD also increased with 0.75 and 1.0 µg ED-71 (0.8, 0.6, and 0.9% from baseline and 0.1, 1.5, and 1.8% vs. placebo group in the 0.5, 0.75, and 1.0 µg ED-71 groups, respectively). Bone formation and resorption markers were suppressed by approximately 20% after 12 months of 0.75 and 1.0 µg ED-71 treatment. Transient hypercalcemia over 2.6 mmol/liter occurred in 7, 5, and 23% of subjects in the 0.5, 0.75, and 1.0 µg ED-71 groups, respectively, but none of them developed sustained hypercalcemia.
Conclusions: These results demonstrate that ED-71 treatment at around 0.75 µg/d can effectively and safely increase lumbar and hip BMD in osteoporotic patients with vitamin D supplementation.
This article has been cited by other articles:
![]() |
N. KUBODERA and S. HATAKEYAMA Synthesis of All Possible A-ring Diastereomers at the 1- and 3-Positions of 1{alpha},25-Dihydroxy-2{beta}-(3-hydroxypropoxy)vitamin D3 (ED-71) Using C2-Symmetrical Epoxide as a Common Starting Material Anticancer Res, September 1, 2009; 29(9): 3571 - 3578. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Bischoff-Ferrari, W. C. Willett, J. B. Wong, A. E. Stuck, H. B. Staehelin, E. J. Orav, A. Thoma, D. P. Kiel, and J. Henschkowski Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency: A Meta-analysis of Randomized Controlled Trials Arch Intern Med, March 23, 2009; 169(6): 551 - 561. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |